biostudies-literatureNie HNanchang University FundingNational Natural Science Foundation of ChinaJiangxi Provincial Health Commission116-135https://www.ebi.ac.uk/biostudies/studies/S-EPMC12063591biostudies-literatureUnknown11(2)<h4>Objective</h4>To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases.<h4>Methods</h4>Mendelian randomization was utilized to analyse data from 500 000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), β-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used.<h4>Results</h4>PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-worEuropean heart journal. Cardiovascular pharmacotherapyLipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.PMC12063591824601032024ZD005820600952023efyA02Wang QZhao WZhou WNie HfalseLipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.<h4>Objective</h4>To assess the impact of lipid-lowering drugs (LLDs) and antihypertensive drugs on the risk of aortic diseases.<h4>Methods</h4>Mendelian randomization was utilized to analyse data from 500 000 participants in the UK Biobank to evaluate the effects of statins, PCSK9 inhibitors (PCSK9i), β-blockers, and calcium channel blockers on the risks of thoracic aortic aneurysm, abdominal aortic aneurysm, and aortic dissection (AD) using genetic variants as proxies. Real-world pharmacovigilance data from the FAERS (FDA Adverse Event Reporting System) database were used.<h4>Results</h4>PCSK9i and statins significantly reduced the risks of aortic aneurysms and AD, respectively. Furthermore, the two LLDs reduced the risk of aortic diseases through certain metabolites. Meanwhile, real-wor2025-01-01T00:00:00Z2025 Mar2026-07-01T03:21:25.965Z2026-07-01T03:12:08.355ZS-EPMC120635913985564410.1093/ehjcvp/pvaf001